GlassScriptPhysician profile
John M Nolte
NPI 1689678211
$1,699.12
in general payments reported to CMS, 2019-2025
21 companies · $47.49 in 2025
The $47.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $190 · 2021: $381 · 2022: $327 · 2023: $96.54 · 2024: $144 · 2025: $47.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $391.69 | 2019-2024 | Wegovy |
| Amgen INC. | $296.17 | 2019-2021 | |
| Abbvie INC. | $220.44 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $200.82 | 2019-2025 | Farxiga, Airsupra |
| Celgene Corporation | $140.96 | 2019 | |
| Pfizer INC. | $74.20 | 2019-2023 | |
| Glaxosmithkline, LLC. | $69.14 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $49.85 | 2019-2022 | |
| Dexcom, INC. | $30.69 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $30.68 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.75 | 2019 | |
| Astellas Pharma US INC | $22.13 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.28 | 2022 | |
| Amarin Pharma, INC. | $19.68 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $19.25 | 2021 | |
| Allergan, INC. | $18.49 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.71 | 2019 | |
| Alkermes, INC. | $17.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nolte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.